3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Glioma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Refractory Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Pancreatic Diseases
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Metastatic Pancreatic Adenocarcinoma
1
Mesothelioma
1
Malignant Solid Neoplasm
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Interventions
Cisplatin
7
Oxaliplatin
5
Paclitaxel
4
Fluorouracil
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
Taxes
3
Mitomycin
3
130-nm albumin-bound paclitaxel
3
Nivolumab
2
Leucovorin
2
Doxorubicin
2
veliparib
1
tremelimumab
1
talimogene laherparepvec
1
soluble LAG-3 protein, human
1
sodium thiosulfate
1
pembrolizumab
1
nintedanib
1
irinotecan sucrosofate
1
durvalumab
1
dehydroftorafur
1
cc-486
1
avelumab
1
Trastuzumab
1
Semaxinib
1
Radiotherapy
1
Radiation
1
Platinum
1
Pharmacogenomic Variants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Peritoneal Neoplasms
×
irinotecan sucrosofate
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled